【脉铂医药】MedBio|1009298-09-2|AZD-8055技术资料

2021-06-10

AZD-8055中文别名:5-[2,4-双[(3S)-3-甲基-4-吗啉]吡啶并[2,3-d]嘧啶-7-基]-2-甲氧基苯甲醇 ;[5-[2,4-二((3S)-3-甲基吗啉-4-基)吡啶并[2,3-d]嘧啶-7-基]-2-甲氧基苯基]甲醇

 

1、AZD-8055用途:
AZD-8055 是一种ATP竞争性的 mTOR 抑制剂,IC50 为 0.8 nM。AZD-8055 抑制 mTORC1 和 mTORC2。

2、AZD-8055物理化学性质:

密度 1.2±0.1 g/cm3
沸点 694.3±65.0 °C at 760 mmHg
分子式 C25H31N5O4
分子量 465.545
闪点 373.7±34.3 °C
精确质量 465.237610
PSA 93.07000
LogP 0.27
蒸汽压 0.0±2.3 mmHg at 25°C
折射率 1.609

 

3、AZD-8055英文别名:

AZD-8055
Benzenemethanol, 5-[2,4-bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxy-
AZD8055
(5-{2,4-Bis[(3S)-3-methyl-4-morpholinyl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol
[5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol

 

4、AZD-8055参考文献:

[1]. Chresta CM, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res, 2010, 70(1), 288-298.

[2]. You W, et al. Inhibition of mammalian target of rapamycin attenuates early brain injury through modulating microglial polarization after experimental subarachnoid hemorrhage in rats. J Neurol Sci. 2016 Aug 15;367:224-31.

[3]. Kawata T, et al. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia. Cancer Sci. 2017 Oct 27.

货号 产品名称 品牌 规格型号 包装 目录价 数量 购物车
MED10667 AZD8055 ,1009298-09-2 MedBio >98% 100mg ¥1615.00
MED10667 AZD8055 ,1009298-09-2 MedBio >98% 10mg ¥427.50
MED10667 AZD8055 ,1009298-09-2 MedBio >98% 200mg ¥2755.00
MED10667 AZD8055 ,1009298-09-2 MedBio >98% 25mg ¥665.00
MED10667 AZD8055 ,1009298-09-2 MedBio >98% 50mg ¥997.50